The survival analysis shown in Figures S8–S10 consistently indicated that high WDHD1 expression was strongly associated with poorer survival status among patients with ACC, BLCA, BRCA, brain cancer, blood cancer, lung cancer, PAAD, SARC, and SKCM. Here, WDHD1 is linked to hematopoietic and lymphoid system neoplasm.